drugset / Trial / NCT02265796
Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Phase 2
Completed
50 enrolled
North Florida Foundation for Research and Education
Gilead Sciences · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study. The study objective is to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients who have demonstrable myocardial ischemia, but who do not undergo revascularization
Timeline
- Start
- 2014-09
- Primary completion
- 2016-05
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranolazine | Small molecule | 1000 mg | — |